{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:25:37Z","timestamp":1794029137233,"version":"4.8.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To examine the association between pregnancy and medications for opioid use disorder (MOUD) initiation and discontinuation among reproductive-aged people receiving treatment for opioid use disorder (OUD) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of people with gender recorded as female, aged 18\u201345 years, in the Merative\n                      <jats:sup>TM<\/jats:sup>\n                      MarketScan\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Commercial and Multi-State Medicaid Databases (2006\u20132016). Opioid use disorder and pregnancy status were identified based on inpatient or outpatient claims for established International Classification of Diseases, Ninth and Tenth Revision diagnosis and procedure codes. The main outcomes were buprenorphine and methadone initiation and discontinuation, determined by using pharmacy and outpatient procedure claims. Analyses were conducted at the treatment episode level. Adjusting for insurance status, age, and co-occurring psychiatric and substance use disorders, we used logistic regression to estimate MOUD initiation and used Cox regression to estimate MOUD discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Our sample included 101,772 reproductive-aged people with OUD, encompassing 155,771 treatment episodes (mean age 30.8 years, 64.4% Medicaid insurance, 84.1% White), of whom 2,687 (3.2%, encompassing 3,325 episodes) were pregnant. In the pregnant group, 51.2% of treatment episodes (1,703\/3,325) involved psychosocial treatment without MOUD, in comparison with 61.1% (93,156\/152,446) in the nonpregnant comparator group. In adjusted analyses assessing likelihood of initiation for individual MOUD, pregnancy status was associated with an increase in buprenorphine (adjusted odds ratio [aOR] 1.57, 95% CI 1.44\u20131.70) and methadone initiation (aOR 2.04, 95% CI 1.82\u20132.27). Discontinuation rates of MOUD at 270 days were high for both buprenorphine (72.4% for nonpregnant episodes vs 59.9% for pregnant episodes) and methadone (65.7% for nonpregnant episodes vs 54.1% for pregnant episodes). Pregnancy was associated with a decreased likelihood of discontinuation at 270 days for both buprenorphine (adjusted hazard ratio [aHR] 0.71, 95% CI 0.67\u20130.76) and methadone (aHR 0.68, 95% CI 0.61\u20130.75), in comparison with nonpregnant status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Although a minority of reproductive-aged people with OUD in the United States are initiated on MOUD, pregnancy is associated with a significant increase in treatment initiation and a reduced risk of medication discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005117","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T10:01:29Z","timestamp":1678442489000},"page":"845-853","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People"],"prefix":"10.1097","volume":"141","author":[{"given":"Kevin Y.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendr\u00e9e E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davida M.","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie C.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony B.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Bierut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"R1-20261107","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts","volume":"132","author":"Schiff","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R2-20261107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1465-3362.2010.00214.x","article-title":"Illicit drug use before and during pregnancy at a tertiary maternity hospital 2000\u20132006","volume":"30","author":"Hayatbakhsh","year":"2011","journal-title":"Drug Alcohol Rev"},{"key":"R3-20261107","doi-asserted-by":"crossref","first-page":"e2021052368","DOI":"10.1542\/peds.2021-052368","article-title":"Perinatal opioid use disorder research, race, and racism: a scoping review","volume":"149","author":"Schiff","year":"2022","journal-title":"Pediatrics"},{"key":"R4-20261107","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13669-016-0168-9","article-title":"Caring for pregnant women with opioid use disorder in the USA: expanding and improving treatment","volume":"5","author":"Saia","year":"2016","journal-title":"Curr Obstet Gynecol Rep"},{"key":"R5-20261107","doi-asserted-by":"crossref","first-page":"e205734","DOI":"10.1001\/jamanetworkopen.2020.5734","article-title":"Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts","volume":"3","author":"Schiff","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R6-20261107","doi-asserted-by":"crossref","first-page":"424.e1","DOI":"10.1016\/j.ajog.2021.04.210","article-title":"Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder","volume":"225","author":"Schiff","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20261107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11920-015-0626-5","article-title":"Substance use in the perinatal period","volume":"17","author":"Forray","year":"2015","journal-title":"Curr Psychiatry Rep"},{"key":"R8-20261107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2015.02.027","article-title":"Perinatal substance use: a prospective evaluation of abstinence and relapse","volume":"150","author":"Forray","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"R9-20261107","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"Jama Pediatr"},{"key":"R10-20261107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pds.4647","article-title":"Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States","volume":"28","author":"Lo-Ciganic","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R11-20261107","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"Jama Netw Open"},{"key":"R12-20261107","doi-asserted-by":"crossref","first-page":"108130","DOI":"10.1016\/j.drugalcdep.2020.108130","article-title":"Age disparities in six-month treatment retention for opioid use disorder","volume":"213","author":"Mintz","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"R13-20261107","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1360-0443.2012.03811.x","article-title":"Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research","volume":"108","author":"Jones","year":"2013","journal-title":"Addiction"},{"key":"R14-20261107","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/pds.3434","article-title":"Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates","volume":"22","author":"Brunelli","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20261107","doi-asserted-by":"crossref","first-page":"e67405","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"key":"R16-20261107","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.3743","article-title":"Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results","volume":"24","author":"Margulis","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R17-20261107","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1176\/appi.ajp.2020.20081174","article-title":"Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis","volume":"178","author":"Xu","year":"2021","journal-title":"Am J Psychiatry"},{"key":"R18-20261107","doi-asserted-by":"crossref","first-page":"107679","DOI":"10.1016\/j.drugalcdep.2019.107679","article-title":"Unmet substance use disorder treatment need among reproductive age women","volume":"206","author":"Martin","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"R19-20261107","first-page":"1","article-title":"Analyzing group level effects with clustered data using Taylor series linearization","volume":"19","author":"Huang","year":"2014","journal-title":"Pract Assess Res Eval"},{"key":"R20-20261107","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3109\/10826084.2013.800116","article-title":"A qualitative study of treatment needs among pregnant and postpartum women with substance use and depression","volume":"48","author":"Kuo","year":"2013","journal-title":"Substance Use Misuse"},{"key":"R21-20261107","doi-asserted-by":"crossref","first-page":"e0226349","DOI":"10.1371\/journal.pone.0226349","article-title":"Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17","volume":"14","author":"Yang","year":"2019","journal-title":"PloS One"},{"key":"R22-20261107","doi-asserted-by":"crossref","first-page":"100225","DOI":"10.1016\/j.ajogmf.2020.100225","article-title":"Barriers to accessing opioid agonist therapy in pregnancy","volume":"2","author":"Bedrick","year":"2020","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R23-20261107","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"New Engl J Med"},{"key":"R24-20261107","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00737-020-01050-y","article-title":"Factors associated with re-initiation of antidepressant treatment following discontinuation during pregnancy: a register-based cohort study","volume":"23","author":"Wikman","year":"2020","journal-title":"Arch Women's Ment Health"},{"key":"R25-20261107","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/pds.3641","article-title":"Prescription of antihypertensive medications during pregnancy in the UK","volume":"23","author":"Cea Soriano","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R26-20261107","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10389-020-01307-x","article-title":"The role of socioeconomic factors on discontinuation of insulin during pregnancy-methodological challenges from a Swedish register-based study","volume":"30","author":"Zhao","year":"2022","journal-title":"J Public Health"},{"key":"R27-20261107","doi-asserted-by":"crossref","first-page":"e2211634","DOI":"10.1001\/jamanetworkopen.2022.11634","article-title":"Analysis of stimulant prescriptions and drug-related poisoning risk among persons receiving buprenorphine treatment for opioid use disorder","volume":"5","author":"Mintz","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R28-20261107","article-title":"Implementation of state laws giving pregnant people priority access to drug treatment programs in the context of coexisting punitive laws","author":"White","year":"2022","journal-title":"Women's Health Issues"},{"key":"R30-20261107","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York city","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res"},{"key":"R33-20261107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11013-019-09634-9","article-title":"A resume for the baby: biosocial precarity and care of substance-using, pregnant women in San Francisco","volume":"44","author":"Premkumar","year":"2020","journal-title":"Cult Med Psychiatry"},{"key":"R34-20261107","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/hec.4518","article-title":"Prenatal substance use policies and newborn health","volume":"31","author":"Meinhofer","year":"2022","journal-title":"Health Econ"},{"key":"R35-20261107","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2018.20851","article-title":"Association among county-level economic factors, clinician supply, metropolitan or rural location, and neonatal abstinence syndrome","volume":"321","author":"Patrick","year":"2019","journal-title":"JAMA"},{"key":"R36-20261107","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/09540261.2021.1898349","article-title":"Addiction treatment in the postpartum period: an opportunity for evidence-based personalized medicine","volume":"33","author":"Martin","year":"2021","journal-title":"Int Rev Psychiatry"},{"key":"R37-20261107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/add.14825","article-title":"Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery","volume":"115","author":"Nielsen","year":"2020","journal-title":"Addiction"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:00:51Z","timestamp":1794027651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005117","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"2022-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}